EGFR
Los inhibidores del receptor del factor de crecimiento epidérmico (EGFR) son compuestos que bloquean la señalización del EGFR, un receptor que a menudo está sobreexpresado en varios tipos de cáncer y que juega un papel crucial en la angiogénesis. Los inhibidores del EGFR se utilizan para prevenir el crecimiento tumoral y las metástasis al interrumpir las vías que promueven la formación de vasos sanguíneos en los tumores. Estos inhibidores son ampliamente utilizados en la investigación y terapia contra el cáncer. En CymitQuimica, ofrecemos una amplia selección de inhibidores de EGFR de alta calidad para apoyar su investigación en oncología y angiogénesis.
Se han encontrado 581 productos de "EGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PROTAC EGFR degrader 2
Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.Fórmula:C58H72ClFN12O8SForma y color:SolidPeso molecular:1151.78Varlitinib Tosylate
CAS:Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).Fórmula:C36H35ClN6O8S3Pureza:98%Forma y color:SolidPeso molecular:811.34PROTAC EGFR degrader 11
CAS:PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR), with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 36 nM. This compound effectively degrades EGFR, focal adhesion kinase (FAK), and RSK1, and inhibits the proliferation of BaF3 wild-type and EGFR mutant cells, exhibiting an IC50 of less than 100 nM.
Fórmula:C49H64ClFN10O7SForma y color:SolidPeso molecular:991.61Herceptide
CAS:Herceptide (HER2-targeting peptide), a peptide that targets HER2, can be conjugated with the near-infrared fluorescent dye indocyanine green (ICG), facilitating the development of theranostic agents.Fórmula:C76H110N22O23Forma y color:SolidPeso molecular:1699.82CZY43
CZY43 is an HER3 degrader that effectively induces degradation of HER3 in breast cancer SKBR3 cells in a dose- and time-dependent manner. It efficiently inhibits HER3-dependent signaling and cancer cell growth, outperforming Bosutinib.Fórmula:C42H53Cl2N5O3Forma y color:SolidPeso molecular:746.808DP-C-4
DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].Forma y color:LiquidDS06652923
DS06652923 is an orally active inhibitor targeting EGFR triple mutations. It exhibits growth-inhibitory effects on Ba/F3EGFRdel19/T90M/C795S cells, with a GI50 value of 9.4 nM. Additionally, DS06652923 induces tumor regression in the Ba/F3 syngeneic transplantation model.Forma y color:Odour SolidDepatuxizumab MMAF
Depatuxizumab-MMAF, an antibody-drug conjugate (ADC), comprises an EGFR-targeted antibody linked to McMMAF and is utilized in glioblastoma research.Forma y color:LiquidPeso molecular:148.24 kDaLyso-Monosialoganglioside GM3
CAS:Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.Fórmula:C41H74N2O20Forma y color:SolidPeso molecular:915.028MS9449
CAS:MS9449 is a powerful EGFR PROTAC; Kd: 17 nM (WT), 10 nM (L858R); targets mutant EGFRs via UPS and autophagy; hinders NSCLC cell growth.Fórmula:C60H76ClFN10O8SPureza:98%Forma y color:SolidPeso molecular:1151.82HER2-IN-13
CAS:HER2-IN-13 (Compound 33) serves as an effective HER2 inhibitor, exhibiting an IC50 value of 8 nM, and additionally demonstrates inhibition of wt-EGFR with anFórmula:C26H23ClF2N8O3Forma y color:SolidPeso molecular:568.96EGFR-TK-IN-5
EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.Fórmula:C26H20ClFN4OSForma y color:SolidPeso molecular:490.98SJF 1521
CAS:SJF 1521 is an EGFR degrader belonging to the PROTAC class that selectively degrades EGFR while preserving HER2.Fórmula:C57H61ClFN7O9SPureza:99.20%Forma y color:SolidPeso molecular:1074.65Simotinib hydrochloride
CAS:Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.Fórmula:C25H27Cl2FN4O4Forma y color:SolidPeso molecular:537.41EGFR-IN-110
EGFR-IN-110 (Compound 6) is a covalent inhibitor of EGFR, demonstrating pIC50 values of 9.2 for the EGFR enzyme and 8.7 for EGFR cells. It exhibits strong efficacy in targeting EGFR and maintains good kinase selectivity.Fórmula:C22H16ClFN4O2Peso molecular:422.09458EGFR kinase inhibitor 2
EGFR kinase inhibitor 2 (compound A-7) is a potent EGFR inhibitor targeting the mutations EGFRL858R/T790M/C797S and EGFRDel19/T790M/C797S. This compound shows potential in addressing acquired resistance in the treatment of non-small cell lung cancer.Fórmula:C39H40N6O5Peso molecular:672.30602EGFR-IN-148
EGFR-IN-148 (compound 8c) is a potent EGFR inhibitor with an IC50 of 0.161 μM. It induces G1/S phase arrest and significantly enhances apoptosis in HepG2 cells.Fórmula:C17H16N4O4SForma y color:SolidPeso molecular:372.398AG-1478 hydrochloride
CAS:AG1478 HCl is an epidermal growth factor receptor protein inhibitor.Fórmula:C16H15Cl2N3O2Forma y color:SolidPeso molecular:352.21EGFR T790M/L858R-IN-9
EGFRT790M/L858R-IN-9 (Compound 8) is an inhibitor targeting the EGFR-L858R/T790M mutations. It effectively inhibits the phosphorylation of the EGFR-L858R/T790M mutant kinase, demonstrating an IC50 value of 0.0064 µM. Additionally, EGFRT790M/L858R-IN-9 can suppress the proliferation of non-small cell lung cancer (NSCLC) cells, making it useful for cancer research.Fórmula:C26H27N7O3SForma y color:SolidPeso molecular:517.603EGFRvIII peptide (PEPvIII)
CAS:PEPvIII, a peptide sequence from EGFRvIII, was designed to represent a target of glioma and is presented by MHC I/II complexes.Fórmula:C70H111N19O24SPureza:98%Forma y color:SolidPeso molecular:1634.81
